Separation of horse dander allergens using two-dimensional PAGE resulted in the identification of 16 proteins that react with allergic patient sera. A sensitive method has been developed for analysing the structures of the glycan chains of individual glycoprotein allergens transferred to blots following two-dimensional PAGE, and has allowed the structural identification of the glycan chains of the most abundant isoforms of Equ c 1, a glycosylated horse dander major allergen. The method involves separation of the allergens by two-dimensional PAGE, transfer to polyvinylidene difluoride membranes, release of the glycan chains using peptide N-glycosidase F, permethylation and mass spectrometric analysis of the derivatised glycans. The amino acid compositions of the 16 horse dander allergens separated by two-dimensional PAGE have been determined, allowing the identification of the various isoforms of Equ c 1. These results also confirmed that the two non-glycosylated major allergens, Equ c 2.0101 and Equ c 2.0102, belong to the lipocalin family, and support the idea that these two allergens are most probably isoforms of the same protein. The glycan structures identified using the mass spectrometric method are common biantennary and triantennary glycan chains. These carbohydrate moieties may have a role in the binding of IgE; however, it is more likely that the overall glycoprotein structure involving both the glycan and protein moieties, rather than the structure of the glycan chains alone, is responsible for eliciting allergic responses.

Keywords:
Amino acid composition, Glycan analysis, Horse dander allergens, Lipocalin proteins, Mass spectrometry
1.
Løwenstein H, Markussen B, Weeke B: Isolation and partial characterization of three major allergens of horse hair and dandruff. Int Arch Allergy Appl Immunol 1976;51:48–67.
2.
Markussen B, Løwenstein H, Weeke B: Allergen extracts of horse hair and dandruff. Quantitative immunoelectrophoretic characterization of the antigens. Int Arch Allergy Appl Immunol 1976;51:25–37.
3.
Franke D, Maasch HJ, Wahl R, Schultze-Werninghaus G, Bretting H: Allergens of horse epithelium. Int Arch Allergy Appl Immunol 1990; 92:309–317.
4.
Fjeldsgaard BE, Smestad Paulsen B: Comparison of IgE-binding antigens in horse dander and a mixture of horse hair and skin scrapings. Allergy 1993;48:535–541.
5.
Johnsen TK, Thanh DB, Ly Q, Smestad Paulsen B, Wold JK: Further characterization of IgE-binding antigens in horse dander, with particular emphasis on glycoprotein allergens. Allergy 1996;51:608–613.
6.
Dandeu JP, Rabillon J, Divanovic A, Carmi-Leroy A, David B: Hydrophobic interaction chromatography for isolation and purification of Equ c 1, the horse major allergen. J Chromatogr 1993;621:23–31.
7.
Gregoire C, Rosinski-Chupin I, Rabillon J, Alzari PM, David B, Dandeu JP: cDNA cloning and sequencing reveal the major horse allergen Equ c 1 to be a glycoprotein member of the lipocalin superfamily. J Biol Chem 1996;271:32951–32959.
8.
King TP, Hoffman D, Løwenstein H, Marsh DG, Platts-Mills TAE, Thomas W: Allergen nomenclature. J Allergy Clin Immunol 1995;96:5–14.
9.
Bulone V, Krogstad-Johnsen T, Smestad-Paulsen B: Separation of horse dander allergen proteins by two-dimensional electrophoresis. Molecular characterisation and identification of Equ c 2.0101 and Equ c 2.0102 as lipocalin proteins. Eur J Biochem 1998;253:202–211.
10.
Mantyjarvi R, Parkkinen S, Rytkonen M, Pentikainen J, Pelkonen J, Rautiainen J, Zeiler T, Virtanen T: cDNA cloning of the predominant allergen of bovine dander: A new member in the lipocalin family. J Allergy Clin Immunol 1996;97:1297–1303.
11.
Rautiainen J, Rytkonen M, Virtanen T, Pentikainen J, Zeiler T, Mantyjarvi R: BDA20, a major bovine dander allergen characterized at the sequence level, is Bos d 2. J Allergy Clin Immunol 1997;100:251–252.
12.
Ball G, Shelton MJ, Walsh BJ, Hill DJ, Hosking CS, Howden ME: A major continuous allergenic epitope of bovine β-lactoglobulin recognized by human IgE binding. Clin Exp Allergy 1994;24:758–764.
13.
Lorusso JR, Moffat S, Ohman JL Jr: Immunologic and biochemical properties of the major mouse urinary allergen (Mus m 1). J Allergy Clin Immunol 1986;78:928–937.
14.
Arruda LK, Vailes LD, Hayden ML, Benjamin DC, Chapman MD: Cloning of cockroach allergen, Bla g 4, identifies ligand binding proteins (or calycins) as a cause of IgE antibody responses. J Biol Chem 1995;270:31196–31201.
15.
Dudler T, Machado DC, Kolbe L, Annand RR, Rhodes N, Gelb MH, Koelsch K, Suter M, Helm BA: A link between catalytic activity, IgE-independent mast cell activation, and allergenicity of bee venom phospholipase A2. J Immunol 1995;155:2605–2613.
16.
Dunbar BS: Two-Dimensional Electrophoresis and Immunological Techniques. New York, Plenum Press, 1987.
17.
Spinelli S, Ramoni R, Grolli S, Bonicel J, Cambillau C, Tegoni M: The structure of the monomeric porcine odorant-binding protein sheds light on the domain swapping mechanism. Biochemistry 1998;37:7913–7918.
18.
Clark AJ, Clissold PM, Al Shawi R, Beattie P, Bishop J: Structure of mouse major urinary protein genes: Different splicing configurations in the 3′-non-coding-region. EMBO J 1984;3:1045–1052.
19.
Shahan K, Gilmartin M, Derman E: Nucleotide sequences of liver, lachrymal, and submaxillary gland mouse major urinary protein mRNAs: Mosaic structure and construction of panels of gene-specific synthetic oligonucleotide probes. Mol Cell Biol 1987;7:1938–1946.
20.
Oates JE, Dell A, Fukuda M, Kukuda MN: A rapid mass-spectrometric procedure for probing the non-reducing structures of lactosaminoglycan-containing glycoconjugates. Carbohydr Res 1985;141:149–152.
21.
Flower DR: The lipocalin protein family: A role in cell regulation. FEBS Lett 1994;354:7–11.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.